CVS · CVS HEALTH Corp
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Up next
Latest documents
CVS Health expects its separation into two independent, publicly traded companies to be completed in the first half of 2028, raised 2026 adjusted EPS guidance to at least $8.20 and forecast at least $8.65 for 2027.
CVS Health plans to separate into CVS Health and CVS Pharmacy in the first half of 2028; nine-month operating income increased $10.4 billion, or 408.2%, as prior-year charges did not recur.
CVS Health intends to separate into a healthcare solutions company and CVS Pharmacy in the first half of 2028; David Joyner and Prem Shah will lead the respective companies as CEOs.
CVS Health reported third-quarter revenue of $108.4 billion, up 5.4%, and Adjusted EPS of $2.09, while raising full-year 2026 GAAP EPS guidance to at least $6.98, Adjusted EPS to at least $8.20 and cash flow to at least $15.5 billion.
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
AI Brief
Q2 FY26 earnings call · Aug 5, 2026TL;DR. CVS Health reported Q2 2026 adjusted EPS of $2.58 (up ~40% YoY) and revenue of $106.1 billion (up 7.3%), raised full-year 2026 adjusted EPS guidance by $0.60 to $7.90–$8.10 and cash flow from operations guidance to at least $11.5 billion, while flagging 340B and Caremark membership declines as 2027 headwinds.
- + Q2 adjusted EPS rose over 40% YoY to $2.58 with adjusted operating income up 35%
- + Q2 revenue grew 7.3% to $106.1 billion with growth across all operating segments
- + Raised full-year 2026 adjusted EPS guidance by $0.60 to $7.90–$8.10
- + Raised full-year 2026 cash flow from operations guidance to at least $11.5 billion (up $2 billion)
- + Health Care Benefits adjusted operating income up 85.5% YoY with MBR improving 250 bps to 87.4%
- + Pharmacy & Consumer Wellness segment delivered over 10% adjusted operating income growth with same-store pharmacy sales up ~3% and prescription volume up 7%
- − 340B program dynamics flagged as a headwind for 2027
- − Caremark expected to see membership declines in 2027 due to selling season dynamics and health plan product actions
- − Medical membership declined ~700K YoY to ~26 million, partly due to exit from individual exchange business
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Research
our published analysis of this companyEquibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Still-open targets the latest release did not restate under the same label.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders NeutralIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EPS non-GAAP | $5.16 | Six Months Ended June 30 | — |
| Adjusted income attributable to CVS Health non-GAAP | 6.62B | Six Months Ended June 30, 2026 | — |
| Adjusted operating income non-GAAP | 10.31B | Six Months Ended June 30 | — |
| Adjusted operating income (loss) - Corporate/Other non-GAAP | -1.05B | Six Months Ended June 30, 2026 | — |
| Adjusted operating loss non-GAAP | -$477M | Three Months Ended June 30, 2026 filing | — |
| Days claims payable | 41.7 | As of June 30, 2026 | — |
| Health Care Benefits Adjusted operating income non-GAAP | 5.47B | Six Months Ended June 30 | — |
| Health Services Adjusted operating income non-GAAP | 3.22B | Six Months Ended June 30 | — |
| Medical benefit ratio ("MBR") | 86% | Six Months Ended June 30 | — |
| Medical membership | 26M | As of June 30, 2026 | — |
| Medicare Prescription Drug Plan (stand-alone) | 3.87M | June 30, 2026 | — |
| People served through health insurance products and related services | 37M | As of June 30, 2026 | — |
| Pharmacy & Consumer Wellness Adjusted operating income non-GAAP | 2.67B | Six Months Ended June 30 | — |
| Pharmacy claims processed | 937.7M | Six Months Ended June 30 | — |
| Plan members | 87M | As of June 30, 2026 | — |
| Prescription volume | 6.9% | Six Months Ended June 30, 2026 | — |
|
|
|||
| Prescriptions filled | 908.2M | Six Months Ended June 30 | — |
| Retail pharmacy locations | 9,000 | As of June 30, 2026 | — |
| Same store sales increase: Front Store | 1% | Q4 | — |
| Same store sales increase: Pharmacy | 2.9% | Q4 | — |
| Same store sales increase: Total | 2.7% | Six Months Ended June 30, 2026 | — |
|
|
|||
| Total medical membership | 26.02M | June 30, 2026 | — |
| Walk-in and primary care medical clinics | 1,000 | As of June 30, 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Healthcare Plans — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CVS
this stock
CVS HEALTH Corp
|
$109.79B | +8.1% | +7.8% | 10.0 | 1.4% |
|
UNH
Unitedhealth Group Inc
|
$349.16B | +18.0% | +11.8% | 22.3 | 1.6% |
|
ELV
Elevance Health, Inc.
|
$93.75B | +23.8% | +12.5% | 18.4 | 2.1% |
|
CI
Cigna Group
|
$77.49B | +6.8% | +11.2% | 13.0 | 2.4% |
|
HUM
Humana Inc
|
$51.07B | +73.1% | +10.1% | 41.3 | 2.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CVS | -3.6% | -9.4% | -7.7% | -4.9% | +8.1% |
| SPY | -2.3% | -4.8% | -2.9% | -3.1% | +7.4% |
| vs SPY | -1.3% | -4.7% | -4.8% | -1.8% | +0.7% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.